Celator Pharmaceuticals Inc.

Celator Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. The company's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies and molecularly targeted agents to deliver enhanced anticancer activity. Celator's lead candidate, CPX-351 (cytarabine:daunorubicin) liposome for injection, is currently being evaluated in a Phase 3 registration study in patients with high-risk (secondary) acute myeloid leukemia, along with other clinical studies.